fig3
Figure 3. We summarize the median progression-free survival for cCRT and cCRT with consolidation immunotherapy through a timeline of median PFS after cCRT without consolidation immunotherapy vs. median PFS after cCRT with consolidation durvalumab as described in ADRIATIC[27]. cCRT: Concurrent chemoradiotherapy; PFS: Progression-free survival.
